NEWAGE INC (NBEV)

US6501941032 - Common Stock

0.0935  -0.03 (-25.2%)

After market: 0.086 -0.01 (-8.02%)

Fundamental Rating

2

NBEV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 37 industry peers in the Personal Care Products industry. NBEV may be in some trouble as it scores bad on both profitability and health. NBEV is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NBEV has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -1.76%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -5.63%
PM (TTM) -1.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

NBEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NBEV has been increased compared to 1 year ago.
NBEV has a better debt/assets ratio than last year.

2.2 Solvency

NBEV has an Altman-Z score of 0.42. This is a bad value and indicates that NBEV is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.07 indicates that NBEV is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC8.09%

2.3 Liquidity

A Current Ratio of 1.42 indicates that NBEV should not have too much problems paying its short term obligations.
A Quick Ratio of 0.92 indicates that NBEV may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 0.92

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.66% over the past year.
The Revenue has grown by 77.07% in the past year. This is a very strong growth!
NBEV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 158.96% yearly.
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q81.82%
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y158.96%
Revenue growth Q2Q58.78%

3.2 Future

Based on estimates for the next years, NBEV will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.05% on average per year.
The Revenue is expected to grow by 13.62% on average over the next years. This is quite good.
EPS Next Y79.08%
EPS Next 2Y36.72%
EPS Next 3Y28.94%
EPS Next 5Y16.05%
Revenue Next Year69.12%
Revenue Next 2Y28.67%
Revenue Next 3Y21.75%
Revenue Next 5Y13.62%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NBEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NBEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.08

4.3 Compensation for Growth

A more expensive valuation may be justified as NBEV's earnings are expected to grow with 28.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y28.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NBEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWAGE INC

NASDAQ:NBEV (9/7/2022, 7:44:56 PM)

After market: 0.086 -0.01 (-8.02%)

0.0935

-0.03 (-25.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.73M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.76%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -5.63%
PM (TTM) -1.62%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.42
Quick Ratio 0.92
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y79.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y